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RESEARCH NOTE
Associations of two-pore domain 
potassium channels and triple negative breast 
cancer subtype in The Cancer Genome Atlas: 
systematic evaluation of gene expression 
and methylation
Keith A. Dookeran1,2* , Wei Zhang3, Leslie Stayner4 and Maria Argos4
Abstract 
Objectives: It is unclear whether 2-pore domain potassium channels are novel molecular markers with differential 
expression related to biologically aggressive triple-negative type breast tumors. Our objective was to systemati-
cally evaluate associations of 2-pore domain potassium channel gene expression and DNA methylation with triple-
negative subtype in The Cancer Genome Atlas invasive breast cancer dataset. Methylation and expression data for all 
fifteen 2-pore domain potassium family genes were examined for 1040 women, and associations with triple-negative 
subtype (vs. luminal A) were evaluated using age/race adjusted generalized-linear models, with Bonferroni-corrected 
significance thresholds. Subtype associated CpG loci were evaluated for functionality related to expression using 
Spearman’s correlation.
Results: Overexpression of KCNK5, KCNK9 and KCNK12, and underexpression of KCNK6 and KCNK15, were significantly 
associated with triple-negative subtype (Bonferroni-corrected p < 0.0033). A total of 195 (114 hypomethylated and 
81 hypermethylated) CpG loci were found to be significantly associated with triple-negative subtype (Bonferroni-
corrected p < 8.22 × 10−8). Significantly negatively correlated expression patterns that were differentially observed 
in triple-negative vs. luminal A subtype were demonstrated for: KCNK2 (gene body: cg04923840, cg13916421), KCNK5 
(gene body: cg05255811, cg18705155, cg09130674, cg21388745, cg00859574) and KCNK9 (TSS1500: cg21415530, 
cg12175729; KCNK9/TRAPPC9 intergenic region: cg17336929, cg25900813, cg03919980). CpG loci listed for KCNK5 and 
KCNK9 all showed relative hypomethylation for probability of triple-negative vs. luminal A subtype. Triple-negative 
subtype was associated with distinct 2-pore domain potassium channel expression patterns. Both KCNK5 and KCNK9 
overexpression appeared to be functionally related to CpG loci hypomethylation.
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Introduction
Two-pore domain potassium (K2p) channels enable 
background leak of potassium (K+) ions and the K2p-
family has 15 members [1, 2]. K2p-channels are impor-
tant for baseline cellular activity at rest including 
membrane-potential, calcium homeostasis and cell-
volume regulation [3]. Evidence from laboratory studies 
supports the hypothesis that alterations in expression/
function of K2p-channels may play a role in cancer devel-
opment/progression [3–5]. The role of K2p-channels 
in breast cancer (BC) is emerging and recent reviews 
suggest potential clinical utility [4, 6, 7]. Williams et  al. 
examined K2p-channel expression in a microarray 
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database study, and reported that all but five members 
showed altered expression in BC [3].
Preliminary reports suggest that some K2p-channels 
may be novel molecular markers with differential expres-
sion related to biologically-aggressive triple-negative 
(TN) type BC. In estrogen-receptor-alpha positive (ER+) 
cell lines, KCNK5 expression appears to be under regu-
latory control of ER-alpha, and estrogen-response-ele-
ments (ERE) are found in the enhancer region of KCNK5 
[8]. Clarke et  al. suggest that upregulation of KCNK5 is 
associated with poor outcome for TNBC-related basal-
like subtype [9]. Conway et al. suggest that KCNK4 may 
be differentially methylated according to race, with rela-
tively higher median DNA-methylation observed for 
non-Hispanic (nH) black vs. nH-white BC [10]. Other 
studies similarly suggest that differential methylation of 
KCNK9 may be related to nH-black race and TNBC [11–
14]. Mu et al. first described the KCNK9 gene on 8q24.3 
as a potential proto-oncogene; gene-amplification (10%) 
and protein-overexpression (44%) were detected in BC, 
but not in normal tissue-controls [15]. DNA copy-num-
ber loss has been observed for KCNK12 in a small clinical 
study of tubular BC [16].
K2p-channels also hold promise for innovative onco-
logic therapeutic/prevention strategies [7, 17, 18]. Current 
molecular-epidemiologic data characterizing K2p-chan-
nels in clinical BC are limited. Our study goal was to 
systematically evaluate associations between K2p-gene-
family mRNA-expression and DNA-methylation with 
TNBC in The-Cancer-Genome-Atlas (TCGA), which con-
tains genomic information from DNA-methylation and 




Publicly available BC data was downloaded/aggregated 
(KAD) from TCGA-Data-Matrix and cBioPortal-for-
Cancer-Genomics (provisional dataset) web-sites (Feb-
ruary 2016) [19, 20]. TCGA molecular BC dataset was 
generated by TCGA-Research-Network and details 
have been previously published [21, 22]. The assembled 
dataset of invasive BC (using TCGA sample-code suf-
fix −01 for primary solid-tumors) included information 
on: (1) clinical-pathological factors: age/stage at diag-
nosis, menopausal status, lymph-node status, estrogen/
progesterone receptor (ER/PR) status, human-epider-
mal-growth-factor-receptor-2 (HER2) status, and race/
ethnicity; and (2) K2p-gene-markers including: (a) Level 
3 DNA-methylation probes (Illumina-Infinium-Human-
Methylation-450K-BeadChip beta-values (450K array), 
n = 767) [23]; and (b) Level 3 RNA-Seq gene-expression 
data (Illumina-HiSeq-platform, gene level RNA-Seq by 
Expectation Maximization (RSEM)-normalized and 
log2-transformed values, n  =  959) [24]. Cytosine–gua-
nine (GpG) methylation loci within 25  kb from either 
end of the genes of interest were included for examina-
tion (UCSC-Genome-Browser [25], hg37); 724 GpG loci 
were included, but was reduced to 608 after exclusion 
of probes with null-reads. Analytic dataset consisted of 
1040 women with information on stage, and all women 
with available data were included in analyses. The study 
was approved by UIC IRB.
Breast cancer subtype
The primary study-endpoint was a binary variable of 
combined TN-status, developed by aggregating data 
from immunohistochemical (IHC) and intrinsic subtype 
assays (PAM50) with a referent of luminal-A status (ER/
PR+/HER2− status). For sensitivity analyses, data on 
Intrinsic Subtype classification was obtained from sup-
plementary publication data based on PAM50 assay [21], 
and data on Integrative Cluster (IC) classification based 
on copy-number-change was obtained from Cancer-
Research-UK-Cambridge-Institute (Oscar Rueda and 
Carlos Caldas) [26–28]. Secondary endpoints in sensi-
tivity analyses included: ER/PR− status (IHC; referent 
ER/PR+); basal-subtype (PAM50; ER/PR−/HER2−, and 
cytokeratin 5/6+ and/or HER1+; referent luminal-A); 
and IC10-type (referent IC3). Gene-expression patterns 
were also compared for RSEM and Agilent arrays.
Statistical methods
For categorical variables, Chi square test-of-association 
was used to examine significance of relationships. For 
continuous variables, t-test was used to compare means 
as appropriate to distribution characteristics; and for 
non-normally distributed data, nonparametric Wilcoxon 
rank-sum test was used.
Tertiles were used for categorization of gene-expres-
sion, except where limited by small sample-signals, 
then binary mRNA-overexpression was defined as a 
z-score  >  +1 standard deviation (SD) [29]. Associa-
tion of all K2p gene-expression and DNA-methylation 
with TN-subtype was evaluated using age (years) and 
race (nH-white, nH-black) adjusted generalized-linear 
regression-models (glm) with binomial-distribution and 
log-link to estimate prevalence risk-ratios (RRs) and their 
corresponding 95% confidence-intervals (CIs). The sig-
nificance threshold for gene-expression and DNA-meth-
ylation was p  <  0.05 and Bonferroni-corrected p-values 
were used where appropriate (Bonferroni-adjusted 
threshold for expression was p < 0.0033; and for methyla-
tion p < 8.22 × 10−8).
Methylation glm results were sorted on p-values (small-
est to largest) and all loci associated with TN-subtype 
Page 3 of 9Dookeran et al. BMC Res Notes  (2017) 10:475 
were selected for reporting and further analysis; loci were 
then evaluated for functionality related to expression 
using Spearman’s correlation. Methylation was deemed 
significantly correlated with expression if the Spearman’s 
Rho-value was either ≤−0.2 or ≥+0.2 and associated 
with a p-value <0.05 [10].
Results
Characteristics of the study sample are presented in 
Table  1. Overall, most of the sample was age >50  years 
(73%), postmenopausal (76%), nH-white (86%), stage-
II (58%), and ER/PR+ (66%) and HER2− (89%); 631 
patients had data on TN (n  =  159) vs. luminal-A 
(n = 472) status.
All K2p gene-expression was non-normally distributed 
(Additional file  1: Table S1). Table  2 demonstrates that 
overexpression of KCNK5/KCNK9/KCNK12, and under-
expression of KCNK6/KCNK15, were associated with 
TN-subtype in age/race adjusted models (all p < 0.0033). 
In fully-adjusted models, KCNK5/KCNK9/KCNK12/K
CNK15 remained associated with TN-subtype.
Gene-expression sensitivity analyses (Additional file 2: 
Table S2) show similar K2p RSEM-expression patterns 
for ER/PR-, basal and IC10 type tumors; however, over-
expression of KCNK7 was also seen with basal-subtype, 
and expression of KCNK9 and KCNK5 was not associ-
ated with basal and IC10 types, respectively. Compara-
tive analyses using the Agilent expression-array (n = 590) 
(Additional file 2: Table S2) shows similar expression pat-
terns for KCNK5/KCNK6/KCNK12/KCNK15, but addi-
tionally shows consistent underexpression of KCNK4 
across subtype, and that KCNK9 was not associated with 
any subtype for this array.
Of 608 CpG loci, 195 (114 hypomethylated and 81 
hypermethylated) loci were found to be associated with 
TN-subtype (p < 8.22 × 10−8, Additional file 3: Table S3). 
Significantly-associated negatively-correlated expres-
sion patterns differentially observed in TN vs. luminal-
A subtype (Table 3; and Additional file 4: Table S4) were 
demonstrated for: KCNK2 (gene-body: cg04923840, 
cg13916421), KCNK5 (gene-body: cg05255811, 
cg18705155, cg09130674, cg21388745, cg00859574) 
and KCNK9 (TSS1500: cg21415530, cg12175729; 
KCNK9/TRAPPC9 intergenic: cg17336929, cg25900813, 
cg03919980). Loci listed for KCNK5/KCNK9 all showed 
relative hypomethylation for probability of TN vs. lumi-
nal-A subtype.
Discussion
K2p RSEM-expression analyses show that specific 
genes are associated with TN-subtype (overexpression 
of KCNK5/KCNK9/KCNK12, and underexpression of 
KCNK6/KCNK15). Sensitivity analyses demonstrate 
consistency; similar RSEM-expression patterns of asso-
ciation were largely evident for ER/PR-, basal and IC10 
related subtypes, although KCNK9 and KCNK5 over-
expression failed to meet significance criteria for basal 
and IC10 types, respectively. Comparative analyses with 
the Agilent-array supports RSEM findings for KCNK5/
KCNK6/KCNK12/KCNK15.
Regarding specificity for association of K2p-expression 
with tumor vs. normal sample-type, we used the MEX-
PRESS web tool for visualizing expression, DNA methyla-
tion and clinical TCGA data [30], and found that KCNK9 
Table 1 Selected characteristics of study sample
nH non-Hispanic, HR hormone receptor, ER/PR estrogen and progesterone 
receptor, HER2 human epidermal growth factor receptor-2
To demonstrate the basic distribution of study covariates:
a An expression ‘flag’ marker (KCNK2) with no missing values is used (mRNA 
Expression z-scores, RNA Seq V2 RSEM)
b A methylation ‘flag’ marker (cg21415530, KCNK9) with no missing values is 
used
Characteristic Gene  expressiona Methylationb
N [%] N [%]
Total 959 [100] 767 [100]
Race
 nH white 592 [85.6] 471 [78.6]
 nH black 100 [14.5] 128 [21.4]
Age (years)
 >/=50 682 [73.3] 477 [71.3]
 <50 248 [26.7] 192 [28.7]
Menopausal status
 Post 653 [76.1] 497 [75]
 Pre 205 [23.9] 165 [25]
Stage
 I 160 [17.3] 126 [17.4]
 II 536 [58] 402 [55.4]
 III 213 [23.1] 188 [25.9]
 IV 15 [1.6] 10 [1.4]
HR expression
 ER+/PR+ 585 [65.6] 452 [65.8]
 ER+/PR− 104 [11.7] 78 [11.4]
 ER−/PR+ 14 [3.3] 15 [2.2]
 ER−/PR− 189 [21.2] 142 [20.7]
Intrinsic subtype
 Luminal A 219 [45] 108 [51.4]
 Luminal B 116 [23.9] 43 [20.5]
 HER2+/HR− 55 [11.3] 14 [6.7]
 Basal-like 88 [18.1] 40 [19]
 Normal-like 8 [1.7] 5 [2.4]
Combined TN status endpoint
 Luminal A 472 [74.8] 398 [76.7]
 Triple negative 159 [25.2] 121 [23.3]
Page 4 of 9Dookeran et al. BMC Res Notes  (2017) 10:475 
(p = 2.58 × 10−9) and KCNK12 (p = 4.63 × 10−10) over-
expression appeared to be associated with tumor type, 
while KCNK5 overexpression appeared to have mar-
ginal association (p  =  0.0757). KCNK6 and KCNK15 
overexpression (associated in our study with luminal-A 
subtype) also appeared to be associated with tumor sam-
ple-type (both p < 2.2 × 10−16).
Specific methylation loci on KCNK2/KCNK5/KCNK9 
were found to be significantly-associated with negatively-
correlated gene-expression and differentially observed 
in TN vs. luminal-A subtype, which suggests potential 
functional significance. All select loci on KCNK5/KCNK9 
had negative delta-beta values indicating relative hypo-
methylation in TN-subtype. The overall levels of nega-
tive expression Rho-values for KCNK5 and KCNK9 were 
more than twice larger for TN than luminal-A subtype. 
Hence it is plausible that KCNK5/KCNK9 overexpression 
related to TN-subtype may be functionally related to spe-
cific tumor CpG loci hypomethylation.
Prior literature suggests KCNK5 may be under control 
of ER-alpha signaling and upregulation is associated with 
worse prognosis for basal-type tumors [8, 9]. Although 
we found association of KCNK5/KCNK9 overexpression 
and TN-subtype, we were unable to relate to prognosis. 
Further, 17-beta-estradiol is known to induce KCNK5 
gene-expression via EREs found in the enhancer region 
of the KCNK5 gene [8]. Hence the observed pattern 
in our study could be interpreted as evidence of loss of 
regulatory control of ER-alpha signaling pathways. An 
alternate explanation could be that KCNK5 gene-expres-
sion in TNBC is incompletely understood. Prior studies 
have implicated KCNK9 as a proto-oncogene in BC and 
suggest importance in TNBC [12–15, 31]. KCNK9 is a 
maternally-imprinted gene with monoallelic-expression 
predominantly in brain tissue, but expression has been 
observed in breast tissue, and both are of ectodermal 
origin [11]. It is theorized that KCNK9 overexpression 
may occur due to acquired relative hypomethylation 
and subsequent functionally biallelic-expression which 
may be equivalent to duplication of an active allele [12]. 
Our findings regarding the functional relationship of 
KCNK9 methylation/expression may be consistent with 
this theory, as we observed increased KCNK9-expression 
together with relative hypomethylation at functional 
loci. We also observed a similar relationship for KCNK5. 
There is scant prior data on KCNK12 expression in BC 
Table 2 Association of K2p gene expression and triple negative subtype
mRNA Expression z-Scores (RNA Seq V2 RSEM)
Reference group for triple negative subtype is luminal A
K2p 2-Pore domain potassium channel, ellipses not applicable
a Models adjusted for race and age, and K2p gene expression is modeled as individual continuous covariates (n = 482)
b Models adjusted for race, age and other selected K2p gene expression variables as continuous covariates, while main K2p gene of interest is modeled as categorical 
tertiles (n = 482); only significant K2p gene expression from univariate glm included
c Fully adjusted model adds stage as an ordinal variable and menopausal status as a binary variable to the mutually adjusted mode; only significant K2p gene 
expression from univariate glm included
d From logistic regression models (glm), Bonferroni adjusted significance threshold = p < 0.0033 (significant values are in italics)
e From glm models p-trend, Bonferroni adjusted significance threshold = p < 0.0033
Age/race  adjusteda Mutually  adjustedb Fully  adjustedc
RR 95% CI p-valued RR 95% CI p-valuee RR 95% CI p-valuee
KCNK1 1.02 0.94 1.10 6.50E−01 … … … … … … … …
KCNK2 0.88 0.63 1.22 4.28E−01 … … … … … … … …
KCNK3 0.95 0.74 1.24 7.25E−01 … … … … … … … …
KCNK4 1.02 0.94 1.10 6.66E−01 … … … … … … … …
KCNK5 1.03 1.02 1.04 2.92E−09 2.51 1.88 3.36 4.26E−10 2.22 1.67 2.96 3.81E−08
KCNK6 0.24 0.17 0.33 1.38E−17 0.87 0.76 0.99 2.96E−02 0.88 0.77 1.01 7.68E−02
KCNK7 0.97 0.90 1.05 5.09E−01 … … … … … … … …
KCNK9 1.02 1.01 1.03 1.43E−03 1.18 1.08 1.30 2.91E−04 1.16 1.06 1.28 2.39E−03
KCNK10 1.06 1.00 1.13 4.44E−02 … … … … … … … …
KCNK12 1.03 1.02 1.04 8.93E−09 1.54 1.36 1.74 4.60E−12 1.54 1.35 1.76 1.74E−10
KCNK13 0.90 0.74 1.08 2.57E−01 … … … … … … … …
KCNK15 0.0036 0.00 0.01 2.21E−19 0.28 0.20 0.38 4.44E−16 0.27 0.19 0.38 2.86E−14
KCNK16 0.0199 0.00 5.31 1.69E−01 … … … … … … … …
KCNK17 1.03 0.91 1.16 6.32E−01 … … … … … … … …
KCNK18 1.03 0.96 1.10 4.55E−01 … … … … … … … …
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Table 3 Annotation and expression correlation for select K2p methylation loci associated with triple negative subtype
Gene GLM  Modelsa Annotationb Luminal  Ac Combined triple  negativec
CpG loci Beta p-value N Rho p-value N Rho p-value
KCNK1
 cg17851113 0.188 1.45E−12 339 0.487 1.31E−21 103 0.301 2.02E−03
 cg23054119 −0.140 3.40E−06 338 0.498 1.37E−22 103 −0.114 2.53E−01
KCNK2
 cg04923840 −0.219 2.00E−25 Body 339 0.227 2.52E−05 103 −0.253 9.81E−03
 cg06873024 −0.183 1.64E−21 Between CENPF/KCNK2 339 0.124 2.21E−02 103 0.241 1.43E−02
 cg24464500 −0.206 9.81E−20 Body 337 0.280 1.70E−07 103 −0.048 6.33E−01
 cg13916421 0.085 1.53E−11 Body 339 0.061 2.60E−01 103 −0.211 3.22E−02
 cg00848374 0.129 2.35E−07 1stExon; 5′UTR 338 0.202 1.83E−04 103 −0.079 4.27E−01
KCNK3
 cg20491914 −0.170 2.97E−11 TSS1500 339 −0.297 2.46E−08 103 −0.164 9.82E−02
 cg11273176 −0.128 1.60E−10 Body 339 −0.388 1.23E−13 103 −0.408 1.88E−05
 cg06854842 −0.090 2.20E−09 Body 339 −0.360 7.91E−12 103 −0.451 1.78E−06
 cg05616379 0.078 1.50E−06 Body 339 −0.221 3.97E−05 103 −0.452 1.64E−06
KCNK4
 cg01708924 −0.185 2.87E−31 3′UTR PRDX5 339 −0.221 3.92E−05 103 0.017 8.68E−01
 cg10718809 −0.148 2.81E−23 PRDX5: body 339 −0.224 3.04E−05 103 −0.026 7.98E−01
 cg10155572 −0.037 1.92E−07 ESRRA: body 339 −0.239 8.75E−06 103 −0.001 9.92E−01
KCNK5
 cg05255811 −0.373 9.32E−70 Body 339 −0.369 2.40E−12 103 −0.674 5.95E−15
 cg18705155 −0.226 2.71E−26 Body 339 −0.120 2.78E−02 103 −0.605 1.33E−11
 cg09130674 −0.224 1.52E−25 Body 339 −0.197 2.65E−04 103 −0.711 3.91E−17
 cg21388745 −0.119 1.81E−23 Body 339 −0.203 1.68E−04 103 −0.701 1.59E−16
 cg00859574 −0.129 4.14E−08 Body 339 −0.160 3.04E−03 103 −0.430 5.90E−06
 cg02128567 −0.113 3.53E−07 1stExon; 5′UTR 339 −0.253 2.35E−06 103 −0.345 3.62E−04
KCNK6
 cg13521973 0.039 6.36E−07 Body 339 −0.244 5.62E−06 103 −0.193 5.07E−02
 cg08216899 −0.025 5.10E−06 3′UTR 339 0.110 4.25E−02 103 0.217 2.75E−02
KCNK7
 cg10142520 −0.210 3.27E−22 EHBP1L1 body 339 −0.215 6.77E−05 103 0.014 8.90E−01
 cg17290213 −0.126 1.09E−17 EHBP1L1 body 339 −0.223 3.57E−05 103 0.092 3.55E−01
 cg03416228 −0.092 6.06E−15 Between EHBP1L1/KCNK7 339 −0.225 2.91E−05 103 −0.171 8.44E−02
 cg12758867 −0.072 2.02E−14 EHBP1L1 body 339 −0.223 3.49E−05 103 0.095 3.38E−01
 cg13179915 −0.067 3.13E−11 1stExon 339 −0.205 1.39E−04 103 −0.305 1.75E−03
 cg05436845 −0.036 6.28E−06 MAP3K11: body 339 −0.223 3.34E−05 103 0.045 6.51E−01
 cg17918700 −0.030 1.55E−05 TSS200 339 −0.230 1.84E−05 103 −0.277 4.55E−03
KCNK9
 cg21415530 −0.332 1.14E−56 TSS1500 339 −0.159 3.32E−03 103 −0.383 6.39E−05
 cg12175729 −0.273 6.23E−22 TSS1500 339 −0.056 3.02E−01 103 −0.215 2.88E−02
 cg20761810 0.155 1.67E−16 Between KCNK9/TRAPPC9 339 0.238 9.24E−06 103 −0.119 2.30E−01
 cg05988964 0.183 2.15E−11 3′UTR 339 0.208 1.16E−04 103 0.197 4.56E−02
 cg17336929 −0.110 9.79E−10 Between KCNK9/TRAPPC9 339 0.055 3.13E−01 103 −0.248 1.17E−02
 cg25900813 −0.106 4.38E−08 Between KCNK9/TRAPPC9 339 0.069 2.07E−01 103 −0.236 1.62E−02
 cg24020826 0.102 7.26E−08 3′UTR 339 0.176 1.12E−03 103 0.204 3.84E−02
 cg18195416 0.125 6.90E−06 Between COL22A1/KCNK9 339 0.206 1.29E−04 103 0.237 1.60E−02
 cg03919980 −0.066 2.96E−05 Between KCNK9/TRAPPC9 339 0.114 3.59E−02 103 −0.222 2.43E−02
KCNK10
 cg09945147 0.219 3.03E−33 Between GPR65/KCNK10 339 0.241 7.35E−06 103 0.312 1.32E−03
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Table 3 continued
Gene GLM  Modelsa Annotationb Luminal  Ac Combined triple  negativec
CpG loci Beta p-value N Rho p-value N Rho p-value
 cg01733928 0.153 4.71E−29 Between GPR65/KCNK10 339 0.250 3.17E−06 103 0.282 3.97E−03
 cg08069902 0.190 9.47E−26 Body 339 0.088 1.07E−01 103 0.231 1.90E−02
 cg02222791 0.225 1.04E−23 Between GPR65/KCNK10 339 0.238 9.06E−06 103 0.267 6.42E−03
 cg18078958 0.219 2.22E−20 Between GPR65/KCNK10 339 0.181 8.11E−04 103 0.290 2.94E−03
 cg10172979 0.123 1.23E−14 Between GPR65/KCNK10 339 0.167 2.01E−03 103 0.286 3.40E−03
 cg24740404 0.167 1.05E−13 Between GPR65/KCNK10 339 0.166 2.12E−03 103 0.211 3.21E−02
 cg15347348 0.134 2.77E−13 Body; TSS1500 339 0.118 2.99E−02 103 0.313 1.27E−03
 cg19453093 0.081 3.20E−12 Body 339 0.205 1.46E−04 103 0.375 9.54E−05
 cg19476426 0.145 2.58E−11 Between GPR65/KCNK10 339 0.172 1.44E−03 103 0.212 3.16E−02
 cg15493607 0.167 4.53E−11 Body; TSS1500 339 0.197 2.64E−04 103 0.313 1.29E−03
 cg17671157 −0.105 6.87E−10 1stExon; 5′UTR 337 −0.068 2.10E−01 103 0.229 1.97E−02
 cg18525616 0.144 8.98E−10 Between GPR65/KCNK10 339 0.156 4.04E−03 103 0.270 5.81E−03
 cg00927624 0.143 3.91E−09 Between KCNK10/SPATA7 339 0.249 3.43E−06 103 0.318 1.08E−03
 cg23291854 −0.107 4.26E−08 1stExon; 5′UTR 339 −0.040 4.65E−01 103 0.282 3.85E−03
 cg22521269 −0.093 1.35E−06 TSS200 339 −0.116 3.35E−02 103 0.215 2.89E−02
 cg02883668 0.079 2.03E−05 Body 339 0.177 1.07E−03 103 0.262 7.40E−03
 cg23381267 0.097 6.14E−05 Body 339 0.154 4.44E−03 103 0.227 2.11E−02
KCNK12
 cg00981060 0.183 1.55E−20 Between MSH2/KCNK12 339 0.073 1.79E−01 103 0.223 2.38E−02
 cg27138584 −0.059 4.47E−05 Body 339 0.003 9.63E−01 103 0.258 8.46E−03
 cg00783525 0.054 7.26E−05 Body 339 0.113 3.70E−02 103 0.335 5.39E−04
KCNK13
 cg21191365 −0.209 2.20E−20 Body 339 −0.026 6.39E−01 103 0.201 4.17E−02
 cg00364611 −0.118 1.32E−11 1stExon 339 −0.170 1.66E−03 103 0.275 4.87E−03
 cg25225073 −0.100 4.05E−07 Body 339 0.073 1.80E−01 103 0.303 1.88E−03
KCNK15
 cg13598409 0.210 1.39E−56 TSS1500 339 −0.251 2.87E−06 103 0.093 3.50E−01
 cg04966972 0.164 7.67E−45 TSS1500 339 −0.298 2.14E−08 103 0.078 4.35E−01
 cg11681959 0.109 5.52E−28 TSS200 339 −0.278 2.01E−07 103 −0.053 5.98E−01
 cg25301532 −0.113 6.12E−09 Body 339 0.253 2.35E−06 103 0.290 2.99E−03
 cg09357268 −0.048 4.75E−08 Body 339 0.195 2.96E−04 103 0.225 2.24E−02
KCNK16
 cg05897803 0.114 3.86E−11 TSS200 339 −0.342 1.04E−10 103 0.009 9.28E−01
 cg07970874 0.087 2.82E−06 TSS200 339 −0.269 4.73E−07 103 0.019 8.47E−01
KCNK17
 cg13855924 −0.142 2.45E−12 Body 339 −0.209 1.09E−04 103 −0.105 2.93E−01
 cg04755571 −0.131 5.17E−10 TSS200 339 −0.241 7.29E−06 103 −0.262 7.62E−03
 cg06347083 −0.124 5.92E−10 TSS200 339 −0.215 6.61E−05 103 −0.216 2.82E−02
 cg10712551 −0.122 1.58E−07 Body 339 −0.175 1.19E−03 103 −0.239 1.49E−02
 cg03252829 −0.105 1.61E−05 1stExon; 5′UTR 339 −0.284 1.04E−07 103 −0.200 4.28E−02
 cg08315770 −0.103 6.55E−05 1stExon 339 −0.205 1.48E−04 103 −0.084 4.02E−01
mRNA expression z-scores (RNA Seq V2 RSEM)
Spearman’s Rho values of <0.2 or >0.2 were considered evidence of correlation if also associated with p-values <0.05 (these values are in italics)
K2p 2-pore domain K+ channel genes, glm generalized linear model
a Age and race adjusted associations of individual methylated CpG loci and combined triple negative vs. luminal A subtype were ranked according to p-value 
(smallest first) and all significant loci were selected for further evaluation (Bonferroni adjusted threshold for methylation analyses = p < 8.22 × 10(−8))
b Annotation data obtained from Illumina for Human Methylation 450K chip array (http://support.illumina.com/array/array_kits/infinium_humanmethylation450_
beadchip_kit/downloads.html)
c Functional correlation between methylation and expression was then examined using Spearman’s correlation and results are presented stratified by subtype
Page 7 of 9Dookeran et al. BMC Res Notes  (2017) 10:475 
and Williams et al. suggested no alteration in their study 
[3]; we found KCNK12 overexpression to be associated 
with TN subtype. Williams et  al. described overexpres-
sion of KCNK6/KCNK15; we found that these were spe-
cifically overexpressed in luminal-A subtype.
Our findings are consistent with prior reports sug-
gesting that some K2p-channels may be novel molec-
ular-markers with differential expression related to 
biologically-aggressive TNBC, and may hold promise for 
innovative oncologic therapeutic/prevention strategies, 
as experience gained with pharmacological manipulation 
of K+ channels in other pathologies, might facilitate their 
use as molecular-targets in precision-medicine [7]. Wal-
lace et al. suggest that K+ channel activity demonstrates 
promise as a pharmacologic target in BC and may rep-
resent a mechanism through which phytoestrogens act 
(e.g. Genistein) [18]. A recent study showed that inhibi-
tion of the intermediate-conductance calcium-activated 
K+ channel KCNN3 with specific blockers including 
the antifungal clotrimazole, suppressed cell prolifera-
tion, migration and epithelial–mesenchymal transition 
in TNBC cells, and illustrates the potential of K+ chan-
nels as novel targets [17]. Sun et al. demonstrated that a 
monoclonal antibody (Y4) against KCNK9 extracellular-
domain effectively inhibits growth of human lung cancer 
xenografts and BC metastasis in mice, and suggest that 
antibody-based KCNK9 targeting is a promising thera-
peutic strategy in KCNK9 overexpressing malignancies 
[32]. Skaar et  al. have been researching whether loss of 
KCNK9 imprint-control and/or differential methylation 
could be adapted in novel approaches for clinical diagno-
sis and targeted therapy for TNBC [11–14].
Conclusions
In summary, our results suggest that several K2p-channel 
methylation/expression markers are related to TNBC. 
KCNK5 and KCNK9 show overexpression and relative 
hypomethylation of specific CpG loci, and have nega-
tive methylation/gene-expression correlations, which are 
features that support functional biology. Study strengths 
include: TCGA is a large, well characterized BC resource; 
we used the target tumor-tissue of interest, not periph-
eral blood; and our findings are consistent with, and build 
on, other reports from TCGA. Our findings are consid-
ered preliminary but may lead to further exploration of 
K2p-channels as potential molecular-targets in preci-
sion-medicine, as pharmacological manipulation of K+ 
channels is currently feasible.
Limitations
TCGA is not a population-based study or clinical trial 
and may be subject to selection bias. There was miss-
ing data on CpG loci with null-reads which may have 
been excluded due to quality-control protocols. Miss-
ing data may cause loss of analytic precision and power 
and could potentially bias results [33]. Our analysis used 
specific CpG probes present on the 450K array, but a 
more comprehensive fine-mapping sequencing approach 
could facilitate interrogation of additional loci. Poten-
tial modeling inadequacies may also result from failure 
to include molecular-markers not available to us, such 
as protein-expression, non-coding RNAs and expres-
sion-quantitative-trait-loci. K2p copy-number-change 
may also be important and this analysis is planned as a 
future study. Regarding survival analysis, specific treat-
ment data is unavailable, and since follow-up time and 
number of survival events are limited, we were unable to 
examine prognosis, as our study is largely under-powered 
to detect differences between groups. Regarding sensi-
tivity analyses, overlap between the RSEM and Agilent 
expression-arrays was only 499 cases, and as such sam-
pling differences could account for observed variation 
in expression profiling. These limitations make the pre-
sent study results preliminary in nature and our findings 
require validation in additional studies.
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